Aquavit Receives FDA Clearance for Two INDs to Initiate Clinical Trials With Its Botulinum Toxin
NEW YORK, April 29, 2023 /PRNewswire/ -- Aquavit Holdings (Aquavit), a biotechnology company focused on the development of botulinum...
top of page
Search
Aquavit Files IND Application for its Flagship Intradermal Injection of Botulinum Toxin
NEW YORK, April 28, 2023 /PRNewswire/ -- Aquavit Holdings (Aquavit), a biotechnology company focused on the development of botulinum...
WIPO Publishes Aquavit's Methods for Delivering Bioactive Compositions and Formulations to the Skin
NEW YORK, March 23, 2023 /PRNewswire/ -- Aquavit Pharmaceuticals, Inc. (Aquavit), a biotechnology company focused on the development of a...
Aquavit Awarded 10M in Damages on Intellectual Property Against Counterfeiters
NEW YORK, March 23, 2023 /PRNewswire/ -- Aquavit Pharmaceuticals, Inc. ("Aquavit") today received a final award in the amount of...
News: Blog2
bottom of page